E-DRUG: Independent Drug and Healthcare Newsletter for March 2021
-------------------------------------------------------------------------
Independant information by and for healthcare professionals
View the contents
If your friends or colleagues would be interested, forward this email and invite them to sign up for the free Newsletter.
Like what you see?
Subscribe to Prescrire International : Prescrire IN ENGLISH - Offers - Subscribe now, or renew subscription - <span style="font-size:13px">Subscribe or renew online</span>
In Prescrire's Spotlight this month:
FEATURED REVIEW
Covid-19: a recap of treatment options. From Prescrire's comprehensive year-end review
Very large amounts of data about covid-19 were published over the past year. As they became available, Prescrire sorted through to determine just which data were useful for the treatment and prevention of the disease.
Read more
-------------------------------------------------------------------
FREE DOWNLOAD
In the March issue of Prescrire International: polatuzumab vedotin (Polivy°) and large B-cell lymphoma
Polatuzumab vedotin has been granted conditional European marketing authorisation for certain patients with relapsed or refractory diffuse large B-cell lymphoma. How do Prescrire's editors rate this option?
Read more
-------------------------------------------------------------------
NEWS UPDATE
Covid-19 and ivermectin: many trials, few results, no proven efficacy
The antiparasitic drug ivermectin has been shown to have in vitro activity against Sars-CoV-2. What are the main results available in early February 2021 from comparative clinical trials of ivermectin in the treatment and prevention of covid-19?
Read more
--------------------------------------------------------------------
EDITORIAL
Doing one's job
The entire health system should be able to count on pharmaceutical companies to do their job, no more, no less. When the roles within the system become blurred, the quality of health care and patients' freedom to choose according to their needs both suffer.
Read more
----------------------------------------------------------------------------
THE PRESCRIRE AWARDS FOR 2020
Annual Prescrire Awards for 2020: 3 winning drugs, including the first "Pilule d'Or" in 6 years
The independent French medical journal Prescrire has published its annual Awards for drugs, drug packaging and information provided by drug companies in 2020. Two drugs made the "Honours List", and Prescrire's "Pilule d'Or" (Golden Pill) was awarded for the first time in 6 years.
Read more
----------------------------------------------------------------------------
REVIEWS
Atopic eczema: avoid tacrolimus (Protopic° and other brands) and pimecrolimus (Elidel°)
In addition to avoiding factors causing skin irritation, the first-line treatment of atopic eczema is still based on application of an emollient and a topical corticosteroid.
Read more
------------------------------------------------------------------------
ADVERSE EFFECTS
Dry eye: sometimes drug-induced
The daily lives of many patients are affected by discomfort and visual disturbances, or even ocular lesions, associated with dry eye syndrome. Drugs are sometimes to blame.
Read more
-------------------------------------------------------------------
OUTLOOK
Comparative trials: an ethical issue
Mounting evidence that hydroxychloroquine (Plaquenil°) lacks the efficacy expected in covid-19 has shown the medical and ethical risks of using drugs on the basis of inadequate evidence.
--------------------------------------------------
Share this with a friend or colleague: Forward this email!